Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH2710 in Advanced Tumors With MAPK Pathway Alterations
CTR20200790Phase 2Terminated
- Sponsor
- Haihe
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HH2710 in Nonhematologic neoplasms, melanoma, non-small cell lung cancer (NSCLC), Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), sponsored by Haihe. Started May 2020; status: terminated.
02
Drugs
HH2710
03
Conditions
Nonhematologic neoplasmsmelanomanon-small cell lung cancer (NSCLC)Langerhans cell histiocytosis (LCH)Erdheim-Chester disease (ECD)
Beyond the preview
Go deeper on CTR20200790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200790.